Enteric-Coated Mycophenolate-Sodium in Heart Transplantation: Efficacy, Safety, and Pharmacokinetic Compared With Mycophenolate Mofetil

Transplantation Proceedings

Volumn 40, Issue 4, 2008, Pages 953-955

  Lehmkuhl, H ^a   Hummel, M ^a,b   Kobashigawa, J ^b   Ladenburger, S ^c   Rothenburger, M ^c   Sack, F ^d   Dengler, T ^d   Hetzer, R ^a  

^a DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NOVARTIS PHARMA GMBH   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ACUTE GRAFT REJECTION; ADULT; AREA UNDER THE CURVE; ARTICLE; CARDIAC GRAFT REJECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG COATING; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; ENTERIC COATED TABLET; EVALUATION; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; HEART TRANSPLANTATION; HUMAN; INFECTION; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISONE; SAFETY; TABLETS, ENTERIC-COATED; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 44849100621     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.03.046     Document Type: Article

References (5)

1. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf 24 (2001) 645
2. Pelletier R.P., Akin B., Henry M.L., et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transpl 17 (2002) 200
3. Knoll G.A., MacDonald I., Khan A., et al. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 14 (2003) 2381
4. Budde K., Glander P., Diekmann F., et al. Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin Pharmacother 5 (2004) 1333
5. Chan L., Mulgaonkar S., Walker R., et al. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation 81 (2006) 1290